For more information on our Expanded Access program, please call 908-574-4770 or email [email protected]. BELLEROPHON THERAPEUTICS Termine - hier erhalten Sie eine Übersicht über alle anstehenden und vergangenen Termine wie Quartalszahlen und Hauptversammlung von BELLEROPHON THERAPEUTICS. After reaching agreement with the U.S. Food and Drug Administration, or FDA, and the European Medicines Agency, or EMA, on its Phase 3 protocol, the company is moving forward with Phase 3 development. Bellerophon has exclusive worldwide rights to the ongoing INOpulse programs and related intellectual property. The data indicates a sustainability of benefit to PAH patients who received INOpulse therapy at the 75 mcg/kg of ideal body weight/hour dose for an average of greater than 12 hours per day and were on long-term oxygen therapy, or LTOT. More About Us, Bellerophon Therapeutics COVID-19 Statement. Bellerophon Therapeutics 184 Liberty Corner Road, Suite 302 Warren, NJ 07059 Ph. AAPL, FB, TWTR), Total amount raised across all funding rounds, Total number of current team members an organization has on Crunchbase, Total number of investment firms and individual investors, Descriptive keyword for an Organization (e.g. Bellerophon focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary diseases. Bellerophon Therapeutics, Inc. est une entreprise de produits thérapeutiques en phase clinique. [])), +((!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![]+[])+(+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![])+(!+[]+(!![])+!![]+!![]+!![])+(!+[]-(!![]))+(!+[]+(!![])+!![]+!![])+(!+[]+(!![])-[])+(!+[]+(!![])+!![]+!![])+(!+[]+(!![])+!![]))/+((!+[]+(!![])+!![]+!![]+!![]+[])+(!+[]+(!![])+!![]+!![]+!![])+(+!![])+(!+[]+(!![])+!![])+(!+[]+(!![])+!![]+!![])+(!+[]-(!![]))+(+!![])+(!+[]+(!![])+!![]+!![]+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![]+!! © 2020 Bellerophon Therapeutics. Bellerophon Therapeutics does control the content of this site and is not responsible or liable for the accuracy of the content presented within any external site. Bellerophon received results from this trial, and have initiated further Phase 2 testing to demonstrate the potential benefit on exercise capacity. The company's third product candidate, bioabsorbable cardiac matrix (BCM), is an injectable device currently undergoing a feasibility clinical trial, which is a CE mark registration trial in the European Union and is comparable to a Phase 2 trial in U.S. drug development, for the prevention of cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction (heart attack). The pages created by the user or by XWiki extensions on behalf of the user. Bellerophon Therapeutics does control the content of this site and is not responsible or liable for the accuracy of the content presented within any external site. During May 2017, Bellerophon announced completion of its Phase 2 study using INOpulse therapy to treat PH associated with idiopathic pulmonary fibrosis, or PH-IPF. The clinical data showed that INOpulse was associated with clinically meaningful improvements in hemodynamics and exercise capacity in difficult-to-treat PH-IPF patients. Please enable Cookies and reload the page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ore About Us Our mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need. The interim analysis for the INOvation-1 study also includes a potential sample size reassessment.